Jessica Sachs

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Joseph M. Connors, Wojciech Jurczak, David J. Straus et al. · New England Journal of Medicine · 2017 · 764 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Efficient Transfer of a Tumor Antigen-Reactive TCR to Human Peripheral Blood Lymphocytes Confers Anti-Tumor Reactivity

Timothy M. Clay, Mary Custer, Jessica Sachs et al. · The Journal of Immunology · 1999 · 407 citations · Full text

Life Sciences, Immunology, Oncology +17

Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen

Michele Pelot, Denise A. Pearson, Kirsten Swenson et al. · Biology of Blood and Marrow Transplantation · 1999 · 173 citations · Full text

Medicine, Hematology, Immunology +15

Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions

Ronjon Chakraverty, Hyeon‐Seok Eom, Jessica Sachs et al. · Blood · 2006 · 101 citations · Full text

Life Sciences, Hematology, Immunology +15

Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study

Franco Locatelli, Christine Mauz‐Koerholz, Kathleen Neville et al. · The Lancet Haematology · 2018 · 100 citations

Medicine, Oncology, Pharmacotherapy +16